Qiagen and Abbott extend distribution agreement:
This article was originally published in Clinica
Diagnostic firms Qiagen and Abbott Laboratories have extended their distribution agreement for Qiagen's RealArt molecular diagnostic tests. Under the revised agreement, Abbott will have non-exclusive distribution rights to certain Qiagen products, including infectious disease tests for hepatitis B virus (HBV), Epstein-Barr virus (EBV), Varicella-Zoster virus (VZM), Parvo B19 virus, cytomegalovirus (CMV), herpes simplex complex and enterovirus. The PCR assays were developed by artus GmbH, a company acquired by Qiagen in May, and use Applied Biosystem's detection instrument. Qiagen is based in Venlo, the Netherlands.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.